GeneDx Holdings (WGS) Invested Capital (2020 - 2026)

GeneDx Holdings (WGS) has reported Invested Capital for 7 consecutive years, with $344.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital rose 3.59% year-over-year to $344.2 million in Q2 2026; TTM through Jun 2026 was $344.2 million, a 3.59% increase from a year earlier, with the FY2025 full-year figure at $356.4 million, up 19.92% from the prior year.
• Invested Capital was $344.2 million for Q2 2026 at GeneDx Holdings, down from $354.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $650.6 million in Q2 2022 and troughed at $250.3 million in Q2 2024.
• A 5-year average of $340.7 million and a median of $322.6 million in 2025 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital soared 218.9% in 2022 and sank 54.62% in 2023, its largest moves.
• Over 5 years, Invested Capital stood at $263.5 million in 2022, then gained by 6.51% to $280.7 million in 2023, then rose by 5.86% to $297.2 million in 2024, then rose by 19.92% to $356.4 million in 2025, then dropped by 3.41% to $344.2 million in 2026.
• The last three Invested Capital figures came in at $344.2 million (Q2 2026), $354.1 million (Q1 2026), and $356.4 million (Q4 2025), per Business Quant data.